Sunshine Biopharma Inc. (SBFM) intrinsic value & 10-year financials
Sunshine Biopharma Inc. (SBFM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 87.4% a year to $36.3M, with an average return on invested capital of -543.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.22
- Market cap
- $155.8K
- Revenue (FY2025)
- $36.3M
- Revenue growth (10-yr CAGR)
- 87.4%
- ROIC (10-yr avg)
- -543.8%
- Free cash flow (FY2025)
- -$5.5M
SBFM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $36.3M | -$6.0M | — | -$5.5M | -17.2% | -42.8% |
| FY2024 | $34.9M | -$5.1M | -$7.32 | -$14.2M | -16.7% | -55.5% |
| FY2023 | $24.1M | -$4.5M | -$0.19 | -$8.9M | -19.9% | -162.3% |
| FY2022 | $4.3M | -$26.7M | -$1.76 | -$5.4M | -621.3% | -10591.4% |
| FY2021 | $228.4K | -$12.4M | -$0.79 | — | -1068.2% | 4486.8% |
| FY2020 | $71.4K | -$2.8M | — | -$658.5K | -807.8% | 316.2% |
| FY2019 | $21.1K | -$1.7M | — | -$496.7K | -3037.9% | -951.6% |
| FY2018 | $447.2K | -$2.2M | — | -$531.7K | -260.9% | -949.4% |
| FY2017 | $0 | -$1.0M | — | -$547.2K | — | 739.0% |
| FY2016 | $0 | -$3.5M | — | -$317.6K | — | 1773.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sunshine Biopharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sunshine Biopharma Inc. has historically struggled to out-earn its cost of capital, averaging just -15.2% ROIC.
Sunshine Biopharma Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Sunshine Biopharma Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-282.83 per share.